You are here

Clinical Trials: Cord Blood

Conditions:   Stroke;   Stroke, Acute;   Brain Injury, Acute
Interventions:   Biological: Umbilical Cord Blood;   Other: Placebo
Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation;   Emory University;   M.D. Anderson Cancer Center
Recruiting - verified March 2017
Condition:   Severe Aplastic Anemia
Interventions:   Drug: Antithymocyte Globulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: UCB HSCT;   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
Recruiting - verified August 2017
Condition:   Cell Transplantation
Interventions:   Drug: Pneumostem;   Drug: Normal saline
Sponsor:   Samsung Medical Center
Recruiting - verified April 2017
Condition:   Deficiency of Anterior Cruciate Ligament
Interventions:   Biological: Cartistem(TM);   Biological: hyaluronic acid;   Procedure: ACL reconstruction only
Sponsor:   Samsung Medical Center
Conditions:   Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Cancer Prevention Research Institute of Texas
Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: NiCord®;   Other: Cord Blood Unit
Sponsor:   Gamida Cell ltd
Recruiting - verified December 2016
Condition:   Inherited Metabolic Disorders (IMD)
Intervention:   Drug: Umbilical cord blood transplantation with HSC835
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2017
Condition:   Hematologic Malignancy
Intervention:   Biological: Transplantation of cord blood expanded with UM171
Sponsors:   Maisonneuve-Rosemont Hospital;   Canadian Cancer Society Research Institute (CCSRI);   Canadian Institutes of Health Research (CIHR);   Hopital de l'Enfant-Jesus;   Vancouver General Hospital;   St. Justine's Hospital
Recruiting - verified March 2017
Condition:   Lymphoma
Interventions:   Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: Methotrexate
Sponsors:   Massachusetts General Hospital;   Adienne SA;   Dana-Farber Cancer Institute
Withdrawn - verified March 2017